

Varun Chawla, MD, MPH

Fremont, CA • 617-407-6207 • varun.chawla@westcoastkidney.com • West Coast Kidney Institute (WKI)

Professional Summary

Board-certified nephrologist (ABIM Internal Medicine & Nephrology) with 12+ years of clinical practice and leadership in community-based kidney care, clinical research, and medical education. Experienced advisor and speaker to biopharma on CKD, IgA nephropathy, hyperkalemia, dialysis, and hypertension. Principal Investigator for multiple ongoing Phase 2/3 programs; committed to pragmatic, high-quality trial execution in diverse populations.

Clinical interests: CKD & diabetic kidney disease, resistant hypertension, hyperkalemia management, dialysis therapies (HD/PD/CRRT), renal bone disease, glomerular diseases including IgA nephropathy.

Current Appointments

Partner, West Coast Kidney Institute (formerly Chabot Nephrology Medical Group) — Fremont, CA (2012–present) - Staff Nephrologist, Washington Hospital (Fremont, CA) - Staff Nephrologist, St. Rose Hospital (Hayward, CA)

Advisory & Industry Experience (Selected)

- Advisor/consultant to **several biopharma companies** across CKD, IgA nephropathy, hyperkalemia, dialysis, and hypertension (2019–present).
 - Contributions typically include protocol/prior-auth/practicality reviews, KOL insights, payer-relevant endpoints, and field-testing of educational materials.
-

Clinical Trial Leadership (Ongoing)

Principal Investigator — WKI Chabot Clinical Research Site (Fremont, CA)

- **BaxDuo—ARCTIC** (Phase 3; NCT06268873). Chronic kidney disease (CKD) + hypertension. Randomized, double-blind study of **baxdrostat + dapagliflozin vs dapagliflozin** alone. **Estimated N ≈ 2,500** across global sites. Design includes a 4-week dapagliflozin run-in, **24-month double-blind** treatment, then a 6-week

open-label dapagliflozin period; primary efficacy assesses CKD progression via GFR reassessment at ~24 months.

- **BaxDuo—PACIFIC** (Phase 3; NCT06742723). CKD + hypertension. Event-driven, randomized, double-blind outcomes study of **baxdrostat + dapagliflozin** vs **dapagliflozin** alone. **Estimated N ≈ 5,000**. Primary composite endpoint: **≥50% sustained eGFR decline, kidney failure, or cardiovascular death**.
 - **RAINIER (povetacicept)** (Phase 3; NCT06564142). **IgA nephropathy. ~480 participants**, randomized, double-blind **povetacicept 80 mg SC q4 weeks** on top of standard of care vs placebo. **Interim** analysis planned at ~36 weeks on **UPCR** for potential accelerated approval; **final primary endpoint**: total **eGFR slope through Week 104**.
-

Areas of Expertise for Advisory Work

- **Therapeutic Areas:** CKD/IgAN, hyperkalemia, RAAS/aldosterone axis, anemia & mineral bone disorder, dialysis access & adequacy.
 - **Clinical Development:** Site selection & feasibility in community nephrology; patient recruitment/retention; protocol practicality; safety monitoring; KOL engagement; payer-relevant endpoints.
 - **Medical Education:** Program design and delivery for HCP audiences; translating evidence to practice.
-

Education & Training

- **Nephrology Fellowship** — Beth Israel Deaconess Medical Center / Harvard Medical School
 - **Internal Medicine Residency** — Mount Auburn Hospital / Harvard Medical School
 - **MPH (Epidemiology & International Health)** — Harvard School of Public Health
 - **MBBS** — All India Institute of Medical Sciences (AIIMS), New Delhi
-

Licensure & Board Certification

- **California Medical License** (active)
 - **ABIM Diplomate:** Internal Medicine (recert. 2021); Nephrology (recert. 2022)
-

Honors & Recognition (Selected)

- America's Most Honored Doctors
- Top Doctors, San Francisco Magazine / Castle Connolly (multiple years)

- Harvard Academy of Educators recognition (fellowship)
-

Publications — Complete List

Non-proteinuric diabetic nephropathy. Chawla V, Roshan B. *Curr Diab Rep*. 2014 Oct;14(10):529.

Geographic disparities in arteriovenous fistula placement in patients approaching hemodialysis in the United States. Goldfarb-Rumyantzev AS, Syed W, Patibandla BK, Narra A, Desilva R, Chawla V, Hod T, Vin Y. *Hemodial Int*. 2014 Jul;18(3):686-94. doi: 10.1111/hdi.12141

Disparities in arteriovenous fistula placement in older hemodialysis patients. Patibandla BK, Narra A, Desilva R, Chawla V, Vin Y, Brown RS, Goldfarb-Rumyantzev AS. *Hemodial Int*. 2014 Jan;18(1):118-26. doi: 10.1111/hdi.12099.

Fistula first is not always the best strategy for the elderly. DeSilva RN, Patibandla BK, Vin Y, Narra A, Chawla V, Brown RS, Goldfarb-Rumyantzev AS. *J Am Soc Nephrol*. 2013 Jul;24(8):1297-304. doi: 10.1681/ASN.2012060632

Access to renal transplantation in the diabetic population—effect of comorbidities and body mass index. Patibandla BK, Narra A, DeSilva R, Chawla V, Goldfarb-Rumyantzev AS. *Clin Transplant*. 2012 May–Jun;26(3):E307-15. doi: 10.1111/j.1399-0012.2012.01661.

Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease. Chawla V, Greene T, Beck G, Sarnak MJ, Menon V. *Clin J Am Soc Nephrol*. 2010 Sep;5(9):1582-7.

Case-control study to identify factors associated with mortality among patients with methicillin-resistant *Staphylococcus aureus* bacteraemia. Marchaim D, Kaye KS, Fowler VG, Anderson DJ, Chawla V, Golan Y, Karchmer AW, Carmeli Y. *Clin Microbiol Infect*. 2010 Jun;16(6):747-52.

Risk factors for albicans and non-albicans candidemia in the intensive care unit. Chow JK, Golan Y, Ruthrazer R, Lichtenberg D, Chawla V, Young J, Hadley S. *Crit Care Med*. 2008 Jul;36(7):1993-8.

Factors associated with non-albicans versus albicans candidemia in the intensive care unit. Golan Y, Ruthrazer R, Lichtenberg D, Chawla V, Young J, Hadley S. *Clin Infect Dis*. 2008 Apr 15;46(8):1206-13.

Textbook chapter

Chawla V, Pollak M. Alport Syndrome. In: Murray MF, Babyatsky MW, Giovanni MA, Alkuraya FS, Stewart DR. (eds.) *Clinical Genomics: Practical Applications in Adult Patient Care*. McGraw-Hill; 2014.

Speaking Engagements — Selected (Recent)

- Faculty/speaker for **multiple CME and industry-sponsored programs** focused on CKD, IgA nephropathy, hyperkalemia, and hypertension (2018–present). Detailed agendas available on request.
-

Professional Societies

American Society of Nephrology • Renal Physicians Association

Disclosures

Advisor/consultant and invited speaker to **several biopharma companies** in nephrology; **Principal Investigator** on ongoing Phase 3 clinical trials noted above. All engagements comply with institutional, payer, and regulatory policies; documentation available upon request.
